Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
RVTY | 54.68% | $11.02B | -13.92% | 0.30% |
AMGN | 53.22% | $158.74B | -1.14% | 3.13% |
REGN | 51.82% | $57.14B | -48.94% | 0.17% |
MTD | 51.73% | $24.01B | -20.58% | 0.00% |
TMO | 51.25% | $152.04B | -29.59% | 0.50% |
TECH | 51.22% | $7.92B | -33.41% | 0.63% |
ZTS | 50.66% | $73.16B | -3.65% | 1.13% |
LYB | 50.01% | $19.32B | -35.75% | 8.85% |
A | 49.65% | $33.26B | -9.83% | 0.82% |
IQV | 49.07% | $27.14B | -26.26% | 0.00% |
MFA | 49.04% | $988.55M | -11.33% | 14.57% |
PPG | 48.46% | $24.13B | -16.51% | 2.52% |
PFE | 48.32% | $139.52B | -10.86% | 6.95% |
LEA | 48.21% | $4.84B | -21.75% | 3.34% |
NDSN | 47.94% | $12.11B | -6.28% | 1.08% |
GNTX | 47.47% | $4.88B | -36.08% | 2.19% |
VC | 47.45% | $2.45B | -13.56% | 0.00% |
BAX | 47.33% | $15.71B | -9.35% | 2.60% |
ITW | 47.11% | $70.75B | +2.68% | 2.42% |
IDXX | 47.08% | $42.04B | +3.71% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
EVRI | -17.66% | $1.23B | +78.21% | 0.00% |
FMTO | -14.51% | $4.90K | -99.92% | 0.00% |
DFDV | -10.47% | $379.06M | +2,332.08% | 0.00% |
HUSA | -9.12% | $24.55M | +27.24% | 0.00% |
TLN | -6.98% | $12.61B | +137.09% | 0.00% |
K | -6.42% | $27.71B | +38.87% | 2.84% |
VHC | -6.28% | $36.37M | +130.03% | 0.00% |
LITB | -5.84% | $23.54M | -75.48% | 0.00% |
OR | -5.49% | $5.02B | +63.71% | 0.69% |
BTCT | -4.81% | $19.24M | +37.16% | 0.00% |
VSTA | -4.47% | $344.07M | +37.94% | 0.00% |
ESGR | -4.38% | $5.00B | +12.61% | 0.00% |
AIFU | -4.07% | $3.21B | -4.38% | 0.00% |
UUU | -3.84% | $7.19M | +93.17% | 0.00% |
CARV | -3.75% | $7.97M | -10.34% | 0.00% |
AGL | -3.64% | $890.00M | -68.84% | 0.00% |
NGVC | -3.63% | $953.36M | +102.54% | 1.09% |
SFM | -3.45% | $15.45B | +108.94% | 0.00% |
VSA | -3.36% | $8.76M | -16.94% | 0.00% |
PULM | -2.44% | $28.52M | +307.26% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
RSPH | 66.01% | $750.00M | 0.4% |
BBH | 65.24% | $341.71M | 0.35% |
IBB | 64.16% | $5.43B | 0.45% |
FXH | 62.98% | $911.90M | 0.62% |
IXJ | 61.95% | $3.86B | 0.41% |
FHLC | 61.87% | $2.48B | 0.084% |
VHT | 61.42% | $15.62B | 0.09% |
IYH | 61.04% | $2.79B | 0.39% |
FBT | 60.63% | $1.03B | 0.54% |
PPH | 60.46% | $595.14M | 0.36% |
XLV | 60.29% | $34.69B | 0.09% |
IHE | 59.95% | $577.23M | 0.39% |
PBE | 59.77% | $226.09M | 0.58% |
XPH | 59.24% | $153.44M | 0.35% |
NOBL | 58.44% | $11.48B | 0.35% |
KNG | 57.85% | $3.78B | 0.75% |
SDY | 56.90% | $19.98B | 0.35% |
MOAT | 56.58% | $12.79B | 0.47% |
SCHD | 55.68% | $70.35B | 0.06% |
FVD | 55.65% | $9.12B | 0.61% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
FTSM | 0.07% | $6.43B | 0.45% |
CORN | 0.35% | $47.63M | 0.2% |
GSST | 0.48% | $898.56M | 0.16% |
IBTI | 0.67% | $1.04B | 0.07% |
FMF | 0.70% | $158.15M | 0.95% |
UUP | -0.70% | $195.17M | 0.77% |
SGOV | -0.70% | $48.84B | 0.09% |
KCCA | -0.82% | $98.43M | 0.87% |
XBIL | -1.50% | $794.88M | 0.15% |
UDN | 1.51% | $146.65M | 0.78% |
STOT | 1.53% | $238.61M | 0.45% |
TDTT | 1.54% | $2.59B | 0.18% |
GLDM | 1.54% | $15.71B | 0.1% |
IBTG | -1.70% | $1.95B | 0.07% |
SGOL | 1.72% | $5.28B | 0.17% |
IAU | 1.82% | $47.53B | 0.25% |
BAR | 1.85% | $1.14B | 0.1749% |
IBTF | -1.89% | $2.08B | 0.07% |
OUNZ | 1.90% | $1.75B | 0.25% |
AAAU | 2.16% | $1.51B | 0.18% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CPSH | 0.09% | $37.77M | +52.24% | 0.00% |
VERX | -0.31% | $5.85B | +4.62% | 0.00% |
CRVO | 0.33% | $61.96M | -62.55% | 0.00% |
PHYS | 0.33% | - | - | 0.00% |
BVN | 0.36% | $4.29B | +0.48% | 0.00% |
DRD | 0.36% | $1.23B | +76.20% | 1.98% |
SMR | 0.37% | $5.18B | +373.99% | 0.00% |
STG | -0.38% | $29.38M | -15.04% | 0.00% |
STRL | -0.56% | $6.17B | +74.49% | 0.00% |
GFI | 0.60% | $23.01B | +89.88% | 2.20% |
OKLO | 0.62% | $8.88B | +572.94% | 0.00% |
CEG | -0.63% | $93.05B | +38.15% | 0.49% |
AEM | 0.68% | $62.92B | +93.71% | 1.30% |
ROOT | 0.70% | $2.36B | +246.01% | 0.00% |
TIGR | 0.79% | $1.41B | +85.91% | 0.00% |
PSQH | 0.80% | $96.54M | -36.34% | 0.00% |
DSP | 0.85% | $790.22M | +32.39% | 0.00% |
IAG | -0.95% | $4.39B | +110.77% | 0.00% |
RLX | -0.98% | $1.96B | +18.13% | 0.46% |
MVO | 0.98% | $67.74M | -34.99% | 21.09% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -34.98% | $181.73M | 0.85% |
TAIL | -34.41% | $104.89M | 0.59% |
IVOL | -26.29% | $358.40M | 1.02% |
BTAL | -19.15% | $291.96M | 1.43% |
XONE | -15.85% | $639.82M | 0.03% |
FTSD | -13.54% | $228.58M | 0.25% |
BIL | -13.18% | $43.88B | 0.1356% |
BILS | -12.24% | $3.93B | 0.1356% |
BILZ | -10.93% | $840.32M | 0.14% |
CLIP | -10.89% | $1.50B | 0.07% |
XHLF | -10.55% | $1.66B | 0.03% |
ULST | -10.53% | $667.54M | 0.2% |
TBLL | -9.61% | $2.24B | 0.08% |
TFLO | -9.46% | $6.90B | 0.15% |
SHYM | -8.03% | $324.56M | 0.35% |
GBIL | -7.73% | $6.18B | 0.12% |
SPTS | -7.28% | $5.78B | 0.03% |
CTA | -6.21% | $1.09B | 0.76% |
BOXX | -5.90% | $6.64B | 0.19% |
UTWO | -5.89% | $375.31M | 0.15% |
Yahoo
Supernus Pharmaceuticals agreed Monday to buy beleaguered biotech Sage Therapeutics in a deal worth up to $561 million.
Finnhub
Supernus Pharmaceuticalswill acquire Sage Therapeutics in a deal worth up to$795 million, gaining access to the only postpartum depressionpill approved in the United States, the companies said...
Yahoo
Biogen Inc. (NASDAQ:BIIB) is one of the 11 most profitable NASDAQ stocks to buy now. On June 12, UCB and Biogen presented additional detailed results from the Phase 3 PHOENYCS GO study, evaluating dapirolizumab pegol (DZP), which is a novel Fc-free anti-CD40L drug candidate. These results were unveiled at EULAR 2025, the European Alliance of […]
Yahoo
A company with profits isn’t always a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Finnhub
Cambridge - Biogen Inc. will host a virtual investor seminar today at 10:00 a.m. ET focused on the potential of the investigational drug felzartamab in rare kidney diseases and the potential to...
Finnhub
Biogen and UCB have announced additional detailed results from the Phase 3 PHOENYCS GO study evaluating their investigational drug dapirolizumab pegol at the annual meeting of the European League...
Current Value
$131.491 Year Return
Current Value
$131.491 Year Return
Double maintains 8 strategies that include BIIB - Biogen, Inc.